Supplemental Information

Mechanism of Polyubiquitination by Human Anaphase-Promoting Complex: RING Repurposing for Ubiquitin Chain Assembly

Data fitting for titrating UBE2S and variants in ubiquitination of Ub-CyclinB<sup>WT</sup> by APC<sup>WT</sup>

Data fitting for titrating UBE2S in di-Ub synthesis by APC variants

Data fitting for titrating Acceptor Ub in di-Ub synthesis by UBE2S and variants in the absence of APC

Data fitting for titrating Acceptor Ub in di-Ub synthesis by APC<sup>WT</sup> with UBE2S and variants

Data fitting for titrating UBE2S in ubiquitination of Ub-CyclinB<sup>WT</sup> by APC<sup>WT</sup> and APC11 RING mutants

Data fitting for titrating Acceptor Ub in di-Ub synthesis by UBE2S and APC<sup>WT</sup> and APC11 RING mutants
Figure S1. Representative fluorescence scans of raw SDS-PAGE data from UBE2S surface mutagenesis and fitting of kinetic data, related to Figure 1.

A, Data from 1st part of 2-part assay identifying UBE2S surfaces mediating APC-dependent ubiquitination. The need for an initiating E2 was bypassed by incorporating the priming Ub into a linear Ub-CyclinB<sup>NTD</sup> fusion fluorescent substrate that is readily polyubiquitinated by APC<sup>CDH1</sup>/UBE2S. Shown are representative fluorescence scans of raw SDS-PAGE data for Ub-CyclinB<sup>NTD*</sup> ubiquitination by APC<sup>CDH1</sup> and UBE2S (wild type and indicated mutant versions). Mutations causing decreased Ub-CyclinB<sup>NTD*</sup> ubiquitination in presence of APC<sup>CDH1</sup> are indicated with green, yellow and cyan dots, and structurally map to the backside of UBE2S' UBC domain, the C-terminal C and D helices of UBE2S' UBC domain, and the UBE2S C-terminal peptide (CTP), respectively. Black dots denote UBE2S mutants defective even in the absence of APC, identified in Fig. S1B. UBE2SΔ5, Δ10, Δ20, and Δ30 variants indicate that residues 181-186, 177-187, 167-187, and 160-190, respectively, were deleted from the UBE2S CTP.

B, 2nd part of 2-part assay identifying UBE2S surfaces mediating APC-dependent ubiquitination, filtering for APC-independent mutational defects by testing effects on UBE2S autoubiquitination. This reaction does not require APC, but as with APC-dependent ubiquitination, requires E1 charging and catalytic placement of the donor and acceptor Ub molecules. Shown are representative fluorescence scans of raw SDS-PAGE data monitoring autoubiquitination by fluorescent *Ub, with wild type UBE2S and the indicated mutant versions that were defective in the assay in Fig. S1A. Mutants specifically defective in APC-dependent ubiquitination shown above are indicated with green, yellow and cyan dots, based on their locations on the UBE2S structure.


C, Titrations of UBE2S (wild type and indicated variants) in assays with fixed concentrations of APC<sup>CDH1</sup> and Ub-CyclinB<sup>NTD*</sup>.

D, Titrations of UBE2S (wild type and indicated variants) in di-Ub synthesis assays with fixed concentrations of APC variants and Ub*.

E, Titrations of acceptor Ub in di-Ub synthesis assays with fixed concentrations of UBE2S (wild type and indicated variants), without APC.

F, Titrations of acceptor Ub in di-Ub synthesis assays with fixed concentrations of APC<sup>CDH1</sup> and UBE2S (wild type and indicated variants).

G, Titrations of UBE2S in assays monitoring ubiquitination of Ub-CyclinB<sup>NTD*</sup>, with fixed concentrations of Ub-CyclinB<sup>NTD*</sup> and APC<sup>CDH1</sup> containing the indicated APC11 variants.

H, Titrations of acceptor Ub in di-Ub synthesis assays with fixed concentrations of APC<sup>CDH1</sup> containing the indicated APC11 variants and UBE2S.
### Table: APC Subcomplex Name vs. APC Subunits

<table>
<thead>
<tr>
<th>APC Subcomplex Name</th>
<th>APC Subunits</th>
<th>Figure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platform Wild Type</td>
<td>APC1, APC4, APC5, APC2, APC11</td>
<td>2C, 2F</td>
</tr>
<tr>
<td>Platform MBP-11</td>
<td>APC1, APC4, APC5, APC2, His_\textsubscript{5}MBP-APC11</td>
<td>2G</td>
</tr>
<tr>
<td>Platform MBP-11 (\Delta)RING</td>
<td>APC1, APC4, APC5, APC2, His_\textsubscript{5}MBP-APC11 ;RING</td>
<td>2C</td>
</tr>
<tr>
<td>APC 2/11</td>
<td>APC2 and APC11</td>
<td>2C, 2F, 3D</td>
</tr>
<tr>
<td>APC (\Delta)APC2 (\Delta)APC11</td>
<td>All APC Subunits except APC2 and APC11</td>
<td>2D</td>
</tr>
<tr>
<td>APC (\Delta)APC2 (\Delta)CTD (\Delta)11</td>
<td>All APC Subunits except APC11, and APC2 residues 1-548 only</td>
<td>2D</td>
</tr>
<tr>
<td>APC (\Delta)APC2 (\Delta)4HB-CTD (\Delta)11</td>
<td>All APC Subunits except APC11, and APC2 residues 1-445 only</td>
<td>2D</td>
</tr>
<tr>
<td>APC CFP-APC4(\Delta)Propeller</td>
<td>All APC Subunits except APC4 residues 1-235 substituted with CFP</td>
<td>2D</td>
</tr>
<tr>
<td>Platform + APC8 + APC15</td>
<td>APC1, APC4, APC5, APC2, APC11, APC8, APC15</td>
<td>2G</td>
</tr>
<tr>
<td>APC (\Delta)APC10</td>
<td>All APC Subunits except APC10</td>
<td>2G</td>
</tr>
<tr>
<td>2/11 (\Delta)RING</td>
<td>APC2 and APC11 (\Delta)RING</td>
<td>3D</td>
</tr>
<tr>
<td>2 4HB-CTD/11</td>
<td>APC2 residues 446-622 and APC11</td>
<td>3D, 6C</td>
</tr>
<tr>
<td>2 4HB-CTD/MBP-11</td>
<td>APC2 residues 446-622 and His_\textsubscript{5}MBP-APC11</td>
<td>3D</td>
</tr>
<tr>
<td>2 4HB-CTD/MBP-11 ;RING</td>
<td>APC2 residues 446-622 and His_\textsubscript{5}MBP-APC11 ;RING</td>
<td>3D</td>
</tr>
<tr>
<td>APC MBP-APC11</td>
<td>All APC Subunits with His_\textsubscript{5}MBP-APC11</td>
<td>4, 5A, 5B, 6A, 6B</td>
</tr>
<tr>
<td>2 4HB-CTD/11 (\Delta)RING</td>
<td>APC2 residues 446-622 and APC11 (\Delta)RING</td>
<td>6C</td>
</tr>
<tr>
<td>APC RING</td>
<td>APC11 residues 17-84</td>
<td>6D, 6E</td>
</tr>
</tbody>
</table>

### Diagrams:

- **Diagram A**: Structure diagrams for various APC subcomplexes and their associated subunits.
- **Diagram B**: Diagrams showing the interaction of UBE2S with UBC Domain and APC subunits.
- **Diagram C**: Western blot analysis showing protein expression for APC1, APC2/3/4, APC5, APC6, APC7/8, and UBE2S.
- **Diagram D**: Gel electrophoresis showing APC subunits.
- **Diagram E**: Western blot analysis showing APC with MBP-APC11.
Figure S2. APC complexes and subcomplexes used in this study, related to Figure 2.

A, Table of APC complexes and subcomplexes, with names used in figures, their constituent APC subunits, and list of main figures in which they are used.


C, Affinity purification of recombinant APC bound to FLAG-tagged UBE2S used for EM. Coomassie-stained SDS-PAGE gel of the cryo-EM APC-UBE2S sample at different stages during the purification is shown. APC complexes used for scanning mutagenesis and immunoprecipitation analyses were purified based on affinity as shown, but those used in kinetic studies were further purified by ion exchange and gel filtration chromatography.

D, Coomassie-stained SDS-PAGE gel of purified APC subcomplexes used for kinetic studies in Fig. 2G.

E, Coomassie-stained SDS-PAGE gel of purified APC complexes containing His6-MBP-APC11 RING mutants used for kinetic studies in Fig. 5B, 6A, 6B.
Figure S3. APC lacking APC10 is properly assembled, as addition of exogenous APC10 restores substrate-dependent ubiquitination activity, related to Figure 3. APC10 is required for processive APC\textsubscript{CDH1}-dependent Ub-CyclinB\textsubscript{NTD}* ubiquitination for both UBCH10 and UBE2S. Given a prior report that APC10 binds UBE2S (Sako et al., 2014), we also generated a version of APC lacking APC10, and validated its expected behavior toward Ub-CyclinB\textsubscript{NTD*}. Without APC10, which binds a substrate’s D-box to enhance processivity of substrate ubiquitination, there was reduced generation of high molecular weight Ub conjugates on Ub-CyclinB\textsubscript{NTD*}, but this was restored by adding bacterially expressed APC10 to reactions. Interestingly, however, deleting APC10 did not substantially influence either the $K_{m,app}$ or $V_{max,app}$ for UBE2S in di-Ub synthesis, which is independent of APC10’s role in recruiting a substrate’s D-box (Fig. 2G). Apparently, APC10 mediates its effects through means other than influencing the fundamental enzymatic function of forming Ub~Ub linkages.
Figure S4. Alanine-scanning mutagenesis of APC11 RING domain within full APC complex, related to Figure 4.

A, Positions of Ala mutants are shown on the structure of the APC11 RING domain as spheres. APC complexes containing RING mutants were generated by coexpression of mutant versions of His₆-MBP-APC11 with all other APC subunits in insect cells. Canonical E2~Ub interacting residues for which mutations impaired ubiquitination by the Ub chain initiating E2s UBCH10 or UBCH5 are shown in green. Positions of mutations preferentially impairing ubiquitination by the Ub chain elongating E2, UBE2S, are shown in pink.

B, Mutations on UBE2S-specific RING surface, but not canonical E2~UB binding surface, impair Ub-CyclinB<sup>NTD*</sup> polyubiquitination by APC<sup>CDC20</sup>/UBE2S. Fluorescence scan of raw SDS-PAGE data.
Figure S5. Structure determination of the human APC11 RING domain, related to Figure 5.

A, Crystal structure of APC11 RING domain in blue with zinc atoms as spheres, shown aligned with structure determined also by NMR (yellow) and the RING domain from RBX1 (green, from 1U6G.pdb, 0.94 RMSD (Goldenberg et al., 2004)). The crystal structure of the APC11 RING is a domain-swapped dimer. The domain swap occurs at the sequence Gln67-Gln68-Val69-Gln70-Gln71. For the figures of the APC11 RING domain structure, residues 21-68 are shown from one protomer, and 70-84 from the opposite protomer in the domain-swapped dimer to generate a single composite RING domain as shown here.

B, Representative electron density for the APC11 RING domain, shown over the surface involved in acceptor Ub recruitment in APC-UBE2S-mediated di-Ub synthesis. The side-chain of Met57 is modeled in two alternative conformations.

C, One domain swapped-dimer from the crystal structure of the APC11 RING domain. Two of four protomers in the asymmetric unit shown in blue and red, respectively, with zinc ions as yellow spheres.

D, Analytical ultracentrifugation data reveals the isolated APC11 RING domain protein samples used in the studies herein is predominantly monomeric in solution. The sedimentation velocity profiles (fringe displacement) were fitted to a continuous sedimentation coefficient distribution model c(s). The experiments were conducted in 25 mM Tris pH 7.6, 100 mM NaCl and 1 mM DTT buffer at 20 °C and at a rotor speed of 50,000 rpm. The measured molecular weight of 8.5 kDa corresponds well with the calculated mass of 8.2 kDa for a monomer.
Figure S6. Structural modeling providing insights into distinctive RING-dependent APC activation of UBE2S-mediated Ub chain elongation, related to Figure 7.

A, Model of a Donor Ub~UBE2S-Acceptor Ub-APC11 RING intermediate. Results of HADDOCK docking of APC11 RING (blue) with the acceptor Ub (orange) is modeled on the structure of the UBE2S UBC domain shown in slate (Sheng et al., 2012), according to (Wickliffe et al., 2011). The donor Ub (yellow) was modeled by aligning the structure of the UBE2S UBC domain and a structure of a Donor Ub~E2 complex (Plechanovova et al., 2012).

B, Structure of the S. cerevisiae E2 Pex4 (pale cyan) in complex with its activator, Pex22 (magenta), involved in a peroxisomal ubiquitination pathway (Williams et al., 2012). Notably, Pex22 interactions with Pex4 helices C and D allosterically activate Ub ligation through poorly defined mechanisms.

C, Compatibility and proximity of multiple modes of APC activation of Ub chain elongation with UBE2S. From APC, the APC11 RING helps recruit the acceptor Ub, and the APC2-APC4 region activates the UBE2S helix D. The interactions are compatible and spatially near each other as shown by superimposing the model in A for APC RING-dependent recruitment of the acceptor Ub to a UBE2S~Ub intermediate, and the UBC domain activation from the peroxisomal pathway in B.
Supplemental Experimental Procedures

Purification of proteins for enzyme assays, coimmunoprecipitation experiments, NMR, and crystallography

Recombinant APC and its subcomplexes were expressed in a baculovirus expression system similar to that described previously (Frye et al., 2013), although the only affinity tag was a twin-Strep tag at the C-terminus of APC4 similar to that used in recent structural studies (Chang et al., 2014). For all experiments other than EM and the experiments shown in Fig. 5A, APC, Platform, and other subcomplexes were purified with a 3-step scheme: Affinity purification with Strep-Tactin Sepharose (IBA Lifesciences) and elution with desthiobiotin, anion exchange, and size exclusion chromatography in a final buffer of 20 mM HEPES pH 8.0, 200 mM NaCl, 1 mM DTT. For the broad mutagenesis screen of RING domain mutants shown in Fig. 5A, APC complexes containing His6-MBP-APC11 were purified by affinity chromatography based on the tag on APC4, with Strep-Tactin Sepharose, but APC incorporating RING mutants studied in Fig. 4, 5B, 6A, 6B, S1, and S4B were all purified using the 3-step scheme.

Wild type and mutant versions of UBE2S were expressed in BL21(DE3) Codon Plus (RIL) cells, from a modified pRSF1b vector with a His6-TEV protease site-FLAG-HRV13 3C protease site-fused to the N-terminus. For the Ala and Trp scanning mutagenesis described in Fig. 1D and S1, these were purified by nickel affinity chromatography, cleaved off the beads with HRV13 3C protease protease, and purified by cation exchange using gravity columns and bump elution with 20 mM TRIS pH 7.6, 400 mM NaCl, 1 mM DTT. Concentrations of mutants were all normalized with this elution buffer prior to use, in order to ensure equal buffer and salt concentrations in assays. UBE2S and mutants used for kinetic and other follow-up enzyme assays (Fig. 1E, 2F-G, 3A-D, 4, 5A-B, 6A-B, 6F, S1C-H, S3 and S4B) were purified by nickel affinity chromatography, eluted, cleaved in solution by HRV13 3C protease, and further purified by cation exchange chromatography and size exclusion chromatography into a final buffer of 20 mM HEPES pH 8.0, 200 mM NaCl, 1 mM DTT. UBE2S and mutants used for FLAG immunoprecipitations in Fig. 2B, C, and D were purified by nickel affinity chromatography, eluted, and further purified by cation exchange using gravity columns and bump elution with 20 mM TRIS pH 7.6, 400 mM NaCl, 1 mM DTT.

N-terminal 3xMYC-His6-CDH1, 3xMYC-His6-CDC20, UBCH10-His6, and human E1 were purified as described previously (Frye et al., 2013; Uzunova et al., 2012). All other proteins were expressed in the BL21-CodonPlus(DE3)-RIL strain of E. coli, except the APC11 RING (residues 17-84) that was expressed in BL21-GOLD(DE3). APC11 RING domain for NMR was expressed as described previously for EMI12T in (Frye et al., 2013). Free APC10 and APC11 were expressed as a TEV protease cleavable N-terminal GST fusions, purified by glutathione-affinity chromatography and treated with TEV protease to cleave off the GST-tag. APC10 was further purified by cation exchange and size exclusion chromatography. APC11 was further purified with size exclusion chromatography. The CyclinBNTD (residues 1-95) and Ub-CyclinBNTD substrates were expressed as N-terminal GST fusions with a C-terminal Cys-His6 tag and purified by nickel affinity chromatography, treated with TEV to remove tags, and polished with size exclusion chromatography. Untagged Ub was purified by an acetic acid precipitation step of unwanted bacterial proteins followed by cation exchange and size exclusion chromatography.

The Ub used as donor in assays in Figs. 1E, 2F-G, 3C-D, 4, 5A-B, 6A, S1C-D, S1G, S3, and S4B, and as acceptor in Figs. 3A-B, 6B, S1E-F, and S1H was purified largely as described previously (Pickart and Raasi, 2005). The fluorescent donor Ub (Ub+) for experiments in Figs. 3A-B, 6B, S1E-F, and S1H and the fluorescent acceptor Ub (Ub*) for experiments in Figs. 2F-G, 3D, and S1D were expressed as a N-terminal GST
fusion and purified by glutathione-affinity chromatography, TEV-mediated proteolytic cleavage of the GST-tag, and size exclusion chromatography. The fluorescent donor and acceptor ubiquitin contained a single cysteine at either position -1 or 77 (G75S:G76S:C77), respectively, for fluorescein-5-maleimide labeling described below. The Ub variants screened for ability to serve as acceptor Ub in Fig. 6F were expressed as Ub (1-74)-Ala-His₆ fusions and purified by nickel affinity chromatography, with buffer matching and removal of imidazole by desalting with PD-10 columns (GE Healthcare: Life Sciences) into 50 mM HEPES pH 7.0, 150 mM NaCl.

**APC-UBE2S complex purification for cryo Electron Microscopy**

APC was initially purified by incubation with Strep-Tactin Sepharose. After washing the Strep-Tactin resin, 5 µM His₆-TEV-PreScission-UBE2S was incubated with resin-bound APC for 1 hour. The resin was washed with 50 mM HEPES pH 8.0, 150 mM NaCl, 2.5% glycerol, 0.05% Tween 20, and the APC-UBE2S complex was eluted with wash buffer supplemented with 2.5 mM desthiobiotin (Sigma). The eluate was then incubated with Anti-FLAG M2 affinity gel (Sigma) for 1 hour, washed with 50 mM HEPES pH 8.0, 150 mM NaCl, 2.5% glycerol, 0.05% Tween 20, and eluted with this wash buffer supplemented with 0.1 mg/ml FLAG peptide. The equivalent of 250 µg of APC-UBE2S was further processed through GraFix (Kastner et al., 2008).

**Cryo Electron Microscopy**

For cryo-EM, the buffer of GraFix-purified fractions was exchanged for 50 mM HEPES pH 8.0, 150 mM NaCl, 2 mM MgCl₂ by desalting (Zeba spin column, Pierce). Particles were adsorbed on carbon film for 1 minute and then mounted on an EM copper grid covered with a perforated carbon film. Specimens were blotted and vitrified (Vitrobot, FEI Company). Images were recorded at a magnification of 74,000x (2 Å/pixel) under cryogenic conditions in a C₃ corrected Titan Krios (FEI Company) electron microscope on a Falcon II direct electron detector (FEI Company). The image dataset was corrected for the CTF (Sander et al., 2003) and particles were iteratively aligned applying resampling to polar coordinates (Sander et al., 2003) and multivariate statistical classification (van Heel, 1984). By computational sorting we found populations of APC particles with UBE2S bound in two distinct conformations and a population where UBE2S was lacking. Both APC/C-UBE2S 3D structures were calculated from ~20,000 particle images and a resolution of 13Å and 23Å were obtained (as judged by the FSC 0.143 criterion, calculated from two independently processed half datasets). Figures were generated using Chimera (Pettersen et al., 2004).

**Enzyme Assays**

The APC/C ubiquitination assays were performed as previously described (Frye et al., 2013), with some differences. The CyclinBNTD and Ub-CyclinBNTD substrates and fluorescent ubiquitins were labeled using fluorescein-5-maleimide (Pierce). Single cysteine proteins were first reduced with 20 mM DTT and desalted twice with Nap5 columns (GE Healthcare: Life Sciences) into 50 mM HEPES pH 7.0, 150 NaCl. The fluorescein-5-maleimide, dissolved in DMSO, was then added in 5-fold molar excess to the protein solution. The reaction was incubated at room temperature for ~2 hours. The reaction was then quenched with 10 mM DTT and subsequently desalted using a PD10 column into 50 mM HEPES pH 7.0, 150 NaCl, 10 mM DTT. Size exclusion chromatography was used to further remove the free fluorescent label using 20 mM HEPES pH 8.0, 200 mM NaCl, 1 mM DTT.

The assays were performed in the same buffer used for gel filtration of APC (20 mM HEPES pH 8.0, 200 mM NaCl, 1 mM DTT). Proteins were mixed on ice containing
APC, ubiquitination substrate (Ub, Ub*, *Ub, CyclinBNTD* or Ub-CyclinBNTD*) in 5 mM MgCl₂, 5mM ATP, 0.25 mg/mL BSA, with 1 µM CDH1 and 0.1 µM E1 and E2. The reaction mixtures were then equilibrated to room temperature before the reactions were initiated by adding 0.2 mM donor Ub. For all kinetic analyses, product bands were quantitated based on a fluorescein label on *Ub, Ub*, or Ub-CyclinBNTD* using a Typhoon FLA 9500 PhosphorImager. For APC-dependent Ub-CyclinBNTD* reactions, APC-independent products were subtracted as background. For APC-independent reactions, products from a negative control reaction that did not contain the acceptor Ub were subtracted as background.

Kinetic experiments to determine the apparent $K_m$ ($K_m^{app}$) and apparent $V_{max}$ ($V_{max}^{app}$) values were determined by fitting the initial velocities to the hyperbolic Michaelis-Menten, $v = V_{max}^{app}[X]/(K_m^{app} + [X])$, equation, where X is either the UBE2S or acceptor Ub concentration, using GraphPad Prism 6 software. Single time points were taken under conditions that satisfy initial velocity regimes. In summary, a time course was monitored at both the minimum and maximum point of each titration to ensure a single time point could be taken where the substrate or UBE2S~Ub depletion is minimal and product formation remained linear. The activity for each quantitative assay was normalized to the $V_{max}^{app}$ of wild-type UBE2S with either APCCDH1 or APCCDH1-NTD depending on the experiment described.

To determine the $K_m^{app}$ and $V_{max}^{app}$ values for UBE2S in assays monitoring Ub-CyclinBNTD* ubiquitination or di-Ub synthesis using Ub* as the substrate, the concentrations were 10 nM or 30 nM APC variant, and 0.5 µM Ub-CyclinBNTD* or 4 µM Ub*. Reactions were quenched after 10 min or 20 min, depending on the components. The assays monitoring Ub transfer to an acceptor Ub* were performed in similar conditions as assays for Ub-CyclinBNTD* ubiquitination assays, except the acceptor substrate was Ub-fluorescein (G755:G765:S:C77). This C-terminal Cys is fluorescently labeled and prevents the Ub-fluorescein from conjugating to either the E1 or E2. For the assays monitoring ubiquitination of Ub-CyclinBNTD*, the data were normalized to the $V_{max}^{app}$ of wild type UBE2S-APCCDH1. For the assays monitoring Ub transfer to Ub*, the data were normalized to the $V_{max}^{app}$ of wild type UBE2S-APCCDH1-NTD.

Qualitative assays probing the function of UBE2S were performed as described above except with concentrations of 14 nM APC, 0.25 µM UBE2S, 0.5 µM Ub-CyclinBNTD* were used (Fig. 1D and S1A). These reactions were quenched at 10 min. The UBE2S autoubiquitination assays (Fig. 1D and S1B) were carried out similarly except (1) the only Ub source was fluorescein-labeled wild type *Ub used at 4 µM concentration; (2) APCCDH1 and Ub-CyclinBNTD* were absent; and (3) the reactions were quenched after 60 min.

Qualitative assays probing the function of His₆-MBP-APC11 RING domain in the context of APC (Fig. 5A) were performed as described above except concentrations of 50 nM APC, 1 µM CDH1, 0.2 µM UBCH5B, UBCH10 or UBE2S, 0.2 µM CyclinBNTD or Ub-CyclinBNTD* were used. These reactions were quenched at 15 min. Qualitative assays in Figs. 4, 5B, and S3 were performed similarly, except the APC concentration is 30 nM APC and in Fig S4B, 0.6 µM CDC20 was used instead of CDH1.

To determine the $K_m^{app}$ and $V_{max}^{app}$ values for the acceptor Ub, 20 µM of the fluorescein-labeled wild-type *Ub was first loaded onto 10 µM E1 in the presence of 5 mM MgCl₂ and 5 mM ATP for 10 min at room temperature. Formation of the E1~*Ub intermediate was quenched with 25 mM EDTA and two passes over desalting columns (Zeba spin column, Pierce) to remove and/or chelate the MgATP to prevent reloading of the E1. The E1~*Ub was then diluted into a second independent mixture (final concentration 2 µM E1~*Ub) that contained unlabeled Ub, BSA, 0.2 µM UBE2S and 0.1 µM APCCDH1, and ubiquitination reactions were then carried out for 3 min. The data were normalized to the $V_{max}^{app}$ of wild type UBE2S-APCCDH1.
For qualitative assays probing the function of the acceptor Ub mutants (Fig. 6F), the E1 charging reaction was started with addition of E1, Ub and MgATP. Formation of the E1~Ub intermediate was quenched by adding EDTA and subsequent desalting. The reaction was then added to a mixture containing UBE2S and Ub or UBE2S, APC\textsubscript{CDH1}, and Ub. The Ub (1-74)-Ala-His\textsubscript{6} fusion variants were screened in the APC\textsubscript{CDH1}-independent and APC\textsubscript{CDH1}-dependent assays at concentrations similar to the apparent $K_{m}^{app}$ values for wild type acceptor Ub as follows: 0.1 $\mu$M APC\textsubscript{CDH1}, 2 $\mu$M UBE2S, and 0.1 mM Ub for 5 min in the APC\textsubscript{CDH1}-dependent assay and 20 $\mu$M UBE2S and 1 mM Ub for 15 min in the APC\textsubscript{CDH1}-independent assay. The UBE2S and Ub concentrations used in APC-dependent and APC-independent assays differ to compensate for the different $K_{m}^{app}$ and $V_{max}^{app}$ values in the presence or absence of APC\textsubscript{CDH1}.

**BPA-UBE2S Protein Expression and Purification**

Amber codons and deletion of CTP “LRRL” residues of UBE2S mutants were introduced into pGEX modified with GST-TEV-FLAG-PreScission. These various amber codon-containing UBE2S constructs were co-transformed into BL21(DE3) with pEVOl-pBpF, a plasmid that encodes aaRS for p-Benzoyl-L-Phenylalanine (BPA) and modified tRNA that repurposes the TAG codon for ribosomal incorporation of BPA (Addgene plasmid 31190) (Young et al., 2010). Proteins were expressed overnight at 23° in auto-induction media and induced simultaneously with 0.02% Arabinose (Sigma), 0.6 mM IPTG, and 0.2 mM BPA dissolved immediately prior to use at 50 mM in 0.7 M NaOH. BPA-UBE2S proteins were purified by glutathione-affinity and cation exchange chromatography. Incorporation of BPA was verified by Intact Mass Spectrometry for the BPA-UBE2S variants (Hartwell Center, St. Jude Proteomics/Mass Spectrometry Facility). p-Benzoyl-L-Phenylalanine (BPA) was purchased from Bachem.

**Photocrosslinking BPA-UBE2S with APC**

Photocrosslinking experiments were performed on ice by mixing BPA-UBE2S with APC-His\textsubscript{6}-MBP-APC11 and 3xMYC-His\textsubscript{6}-CDH1 at 1 $\mu$M. Following a 60-minute exposure to 365nm UV light (Bulb ID: 34-0009-01) proteins were separated by 15% (FLAG-UBE2S blot) or 8% (APC subunit blots) SDS-PAGE. The following commercial antibodies were used for detection in crosslinking studies by western blotting using standard methods: APC1 (SC-20983, SCBT), APC2 (12301, Cell Signaling Technology), APC4 (SC-21414, SCBT), APC11 (14090, Cell Signaling Technology), Strep-Tag II (Ab76949, Abcam), FLAG (F1804, Sigma-Aldrich), and c-MYC (SC-40, SCBT). Polyclonal APC5 antibodies were generated at Gramsch Laboratories against a synthetic peptide (ELTSRDERGKMEKEEL).

**X-Ray Crystallography**

APC 11 RING domain (residues 17-84) was purified in 25 mM TRIS pH 7.6, 100 mM NaCl, 1 mM DTT. Crystals were grown with the hanging drop vapor diffusion method in 16% PEG 3350, 0.2 M NaNO\textsubscript{3}, 0.1 M BIS-TRIS Propane pH 6.5 and set at room temperature with 30 mg/mL APC11 RING domain. The mother liquor including 40% PEG 3350 was used as a cryoprotectant. The data were collected at NECAT ID-24C at the Zn peak energy. The data were integrated and scaled using the NECAT RAPD software (https://rapd.nec.aps.anl.gov/rapd). The initial phasing electron density was obtained with zinc SAD using SHELEX (Sheldrick, 2008). Model construction and refinement were done in Coot (Emsley and Cowtan, 2004; Emsley et al., 2010) and Phenix (Adams et al., 2010).
NMR Spectroscopy

NMR samples were purified in 20 mM Hepes pH 7.0, 100 mM NaCl, 10 mM DTT dissolved in 90% H2O/10% D2O buffer. All the titration data were collected as 2D [15N, 1H] TROSY spectra at 298K with a Bruker 800 MHz spectrometer equipped with a 1H and 13C detector, TCI triple resonance cryogenic probe on 15N-labeled samples. The assays monitoring chemical shift perturbations upon adding APC2<sup>13</sup>HBD<sup>13</sup>TD/APC11±RING to 15N-labeled Ub were performed at concentrations of 0.24 mM and 0.1 mM, respectively. An APC11 RING titration ranging from 0.1 - 1.3 mM was added to 0.2 mM 15N-labeled Ub. An Ub titration ranging from 0.2 - 3 mM was added to 0.1 mM 15N-labeled APC11 RING. RING domain assignment experiments were carried out on 15N, 13C labeled APC11 RING at 500 μM concentration. APC11 RING domain backbone resonance 3D NMR experiments were measured on aBruker 600 MHz spectrometer equipped with a 1H and 13C detect, TCI triple resonance cryogenic probe using standard Bruker pulse programs. 1H, 13C, and 15N backbone resonances were assigned using standard triple resonance experiments, such as HNCA, CBCA(CO)NH, HNCO and HN(CA)CO. Side chain assignments were carried out using 15N-resolved TOCSY, 13C-resolved H(C)CH TOCSY and (H)CCH TOCSY experiments. Aromatic side chains were assigned using the 13C-resolved aromatic NOESY spectra along with the TOCSY. All the 1H chemical shifts were referenced with respect to DSS measured in the same buffer, while the 13C and 15N chemical shifts were referenced indirectly with respect to the DSS shift. All of the spectra were processed using TopSpin software and analyzed using the computer-aided resonance software, CARA (Keller, 2004). Ubiquitin assignments were taken from BMRB entry 15410 (Wong et al., 2008). The chemical shift perturbations were calculated using, 

\[ \text{CSP(ppm) = } \frac{\theta}{2} + \frac{(1/2)(\Delta\delta N)^2}{(\Delta\delta H)^2} \]

where \( \Delta\delta H \) and \( \Delta\delta N \) represents the chemical shift difference between the free and complex for 1H and 15N resonances respectively.

Structures were determined using a combination of manually assigned NOEs and automatic NOE assignment using the program CYANA (Guntert et al., 1997). Approximately 872 meaningful distance restraints, 32 angle restraints derived from CA, CB shifts using program TALOS+(Shen et al., 2009), 12 zinc ion distances and 18 hydrogen bond restraints based on exchange cross peaks with water in the 15N-NOESY spectrum, were used in the structure calculation of APC11 RING. Seven iterations of refinement of 100 structures per cycle were completed, after proper distance calibrations. After the initial fold of the protein was determined, a CYANA amino acid library using a modified zinc ligated cysteine residue was used to incorporate the three zinc ions into the structures. Parameters used in the structure calculation are given in Table 2.

Analytical Ultracentrifugation

Sedimentation velocity experiments were conducted in a ProteomeLab XL-I analytical ultracentrifuge (Beckman Coulter, Indianapolis, IN) following standard protocols unless mentioned otherwise (Zhao et al., 2013a). The sample in a buffer containing 25 mM Tris pH 7.6, 100 mM NaCl, and 1 mM DTT was loaded into a cell assembly comprised of a double sector charcoal-filled centerpiece with a 12 mm path length and sapphire windows. The density and viscosity of the ultracentrifugation buffer at 20 °C were measured with a DMA 5000M density meter and an AMVn viscometer (both Anton Paar, Graz, Austria) respectively. The cell assembly, containing identical sample and reference buffer volumes of 400 μL, was placed in a rotor and temperature equilibrated at 20 °C at rest for 2 hours before it was accelerated from 0 to 50,000 rpm. Rayleigh interference optical data were collected at 1-minute intervals for 12 hours. The velocity data were modeled with diffusion-deconvoluted sedimentation coefficient distributions c(s) in SEDFIT (https://sedfitsedphat.nibib.nih.gov/software/default.aspx), using algebraic noise decomposition and with signal-average frictional ratio and meniscus position refined with
non-linear regression. The s-value was corrected for time, temperature and radial position and finite acceleration of the rotor was accounted for in the evaluation of Lam equation solutions (Ghirlando et al., 2014; Zhao et al., 2013b). Maximum entropy regularization was applied at a confidence level of P-0.68.

**Computational modeling APC11 RING-Acceptor Ub interactions**

We used Haddock 2.1 (de Vries et al., 2007; Dominguez et al., 2003) for constructing the RING-Acceptor Ub complex. The HADDOCK run produced an ensemble of 200 structures, which were clustered by applying backbone root-mean-square deviation (rmsd) cut-off of 7.5 angstrom after two-step HADDOCK simulations. To model the RING-Acceptor Ub complex, the crystal structure of the APC11 RING domain was docked to a single Ub molecule. The binding interface of the RING domain and acceptor Ub was defined from NMR chemical shift perturbation data by mutual titrations of the RING domain and ubiquitin. Two loops of the acceptor Ub, residues 8-10 and 72-76, were set as flexible residues in explicit solvent refinement stage, to allow the system to fully explore more favorable conformations of these regions while maintaining the overall complex architecture. Interactions of side chains with three zinc ions were kept during simulations by adding additional unambiguous distance restraints. The simulation generated 2 clusters. The cluster 1 contains 87% of all modeled structures with better average binding affinity within the top ranked four structures as shown below:

The calculated binding free energies of top ranked models in the two HADDOCK clusters.

<table>
<thead>
<tr>
<th>Number of Structures&lt;sup&gt;b&lt;/sup&gt;</th>
<th>E&lt;sub&gt;tot&lt;/sub&gt;&lt;sup&gt;c&lt;/sup&gt; (kcal/mol)</th>
<th>E&lt;sub&gt;vdw&lt;/sub&gt;&lt;sup&gt;d&lt;/sup&gt; (kcal/mol)</th>
<th>E&lt;sub&gt;elec&lt;/sub&gt;&lt;sup&gt;e&lt;/sup&gt; (kcal/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cluster 1 (top 4)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>164</td>
<td>-3.37 +/- 0.22</td>
<td>-0.83 +/- 0.30</td>
</tr>
<tr>
<td>Cluster 2 (top 4)</td>
<td>26</td>
<td>-0.63 +/- 0.63</td>
<td>-0.50 +/- 0.49</td>
</tr>
</tbody>
</table>

<sup>a</sup> The top four models with best binding free energies from each cluster were used to determine the average binding free energies and standard deviations.

<sup>b</sup> Indicates that the number of structures in each cluster which share similar conformations with backbone rmsds within 7.5 angstroms.

<sup>c</sup> E<sub>tot</sub> indicates the total binding free energy.

<sup>d</sup> E<sub>vdw</sub> indicates the average van der waals interaction energy.

<sup>e</sup> E<sub>elec</sub> indicates the average electrostatic interaction energy.
SUPPLEMENTAL REFERENCES


